Objective Quantitation of EGFR Protein Levels using Quantitative Dot Blot Method for the Prognosis of Gastric Cancer Patients

Lei Xin; Fangrong Tang; Bo Song; Maozhou Yang; Jiandi Zhang

doi:10.5230/jgc.2021.21.e32

추천

검색

자료유형: 학술저널

저자정보: Lei Xin (Yantaishan Hospital) Fangrong Tang (Yantai Quanticision Diagnostics Inc. (Division of Quanticision Diagnostics Inc. of USA)) Bo Song (Yantaishan Hospital) Maozhou Yang (Yantai Quanticision Diagnostics Inc. (Division of Quanticision Diagnostics Inc. of USA)) Jiandi Zhang (Yantai Quanticision Diagnostics Inc. (Division of Quanticision Diagnostics Inc. of USA))

저널정보: 대한위암학회 Journal of Gastric Cancer Journal of Gastric Cancer 제21권 제4호

발행연도: 2021.12

수록면: 335 - 351 (17page)

DOI: 10.5230/jgc.2021.21.e32

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Purpose: An underlying factor for the failure of several clinical trials of anti-epidermal growth factor receptor (EGFR) therapies is the lack of an effective method to identify patients who overexpress EGFR protein. The quantitative dot blot method (QDB) was used to measure EGFR protein levels objectively, absolutely, and quantitatively. Its feasibility was evaluated for the prognosis of overall survival (OS) of patients with gastric cancer. Materials and Methods: Slices of 2×5 μm from formalin-fixed paraffin-embedded gastric cancer specimens were used to extract total tissue lysates for QDB measurement. Absolutely quantitated EGFR protein levels were used for the Kaplan-Meier OS analysis. Results: EGFR protein levels ranged from 0 to 772.6 pmol/g (n=246) for all gastric cancer patients. A poor correlation was observed between quantitated EGFR levels and immunohistochemistry scores with ρ=0.024 and P=0.717 in Spearman's correlation analysis. EGFR was identified as an independent negative prognostic biomarker for gastric cancer patients only through absolute quantitation, with a hazard ratio of 1.92 (95% confidence interval, 1.05?3.53; P=0.034) in multivariate Cox regression OS analysis. A cutoff of 208 pmol/g was proposed to stratify patients with a 3-year survival probability of 44% for patients with EGFR levels above the cutoff versus 68% for those below the cutoff based on Kaplan-Meier OS analysis (log rank test, P=0.002). Conclusions: A QDB-based assay was developed for gastric cancer specimens to measure EGFR protein levels absolutely, quantitatively, and objectively. This assay should facilitate clinical trials aimed at evaluation of anti-EGFR therapies retrospectively and prospectively for gastric cancer.

#Epidermal growth factor receptor #QDB #Companion assay #Cetuximab #Necitumumab

참고문헌 (49)

참고문헌 신청

Díaz-Serrano A / 2019 / Necitumumab for the treatment of advanced non-small-cell lung cancer / Future Oncol 15:705~716

Pirker R / 2012 / EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer : analysis of data from the phase 3 FLEX study / Lancet Oncol 13:33~42

Paz-Ares L / 2015 / Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer(INSPIRE) : an open-label, randomised, controlled phase 3 study / Lancet Oncol 16:328~337

Apicella M / 2017 / Targeted therapies for gastric cancer : failures and hopes from clinical trials / Oncotarget 8:57654~57669

Li K / 2016 / Current molecular targeted therapy in advanced gastric cancer : a comprehensive review of therapeutic mechanism, clinical trials, and practical application / Gastroenterol Res Pract 2016:4105615

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!